

EMN Guideline Team: Update 2023

M. Engelhardt, E. Terpos, N. van de Donk, F. Gay


Scientific advice: Sonneveld, Ludwig, Einsele et al.

<https://www.myeloma-europe.org/emn/about-emn/>

15th EMN Trialists forum: EMN. 5.-6. November, 2023



Publication flow via authors, guideline team and EMN board



Responsibility of EMN members: to support & closely interact with guideline team

Citation of EMN guideline / consensus papers essential to increase EMN visibility

Publication flow -> on EMN homepage + EMN productivity

See also EMN Publication Policy on the website

<https://www.myeloma-europe.org/>

First, log in → then click on “EMN” → “Policies & Templates”

Pubmed search „EMN“: 102

last 5 years: **63 papers**

Last 1 y: 13

EMN reviews/ guidelines/ consensus

EMN members can collaborate on reviews/ guidelines/ consensus papers to communicate the EMN perspective on treatments and other relevant topics.

A publication plan is agreed with the “guideline team” of the EMN. They are few members (reported on the EMN website) who encourage colleagues to write manuscripts and coordinate the various topics. This is fundamental to avoid duplicates or overlapping papers.

EMN members can propose the topic of an EMN manuscript (usually during operative meetings of the EMN), and, if accepted, this is included in the publication plan. The person who proposes the topic becomes the lead author and is responsible for moving the publication forward.

The EMN staff can provide the lead author with a list of EMN members and their respective fields of interest/ main expertise. The lead authors can select the experts they wish to collaborate with (they can use the list provided by the EMN staff and/or they can refer to their own contacts). The guideline team can also support the lead author suggesting relevant professionals that might be helpful to include, according to the topic of the paper, and can suggest target journals.

The lead author is responsible for making the submission and interacting with the journal staff also during the reviewing, final acceptance and publication processes.

Pubmed search, last 1y: “EMN AND MM”

n=102

Excluded older than 2022/2023

Last 1 y: n=13

Topics	# of publications	Journals
2. revision R2-ISS	1	JCO 2022
Prevention AEs	1	Lancet oncol 2023
Covid-19	2	Leukemia 2023
HR, imaging, biomarkers, exome seq	4	Front oncol 2023, Med Pharm Rep 2022, Int J Mol Sci 2023, Front cardiovasc Med 2023
Costs	1	Hemasphere 2023
Clinical trials, HRQoL,Herbicides	4	Nat Med 2023, Lancet Hematol 2022, Patient 2023, Occp Environ Med 2022

[Second Revision of the International Staging System \(R2-ISS\) for Overall Survival in Multiple Myeloma: A D'Agostino M et al.. *J Clin Oncol.* **2022**;40:3406-3418](#)

[Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells Ludwig H et al. *Lancet Oncol.* **2023**;24:e255-e269](#)

[Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus pa Terpos E et al. *Leukemia.* **2023**;37:1175-1185](#)

[Convalescent plasma for patients with multiple myeloma and COVID-19: the European Myeloma Netwo Terpos E, Musto P, Engelhardt M, Ntanasis-Stathopoulos I, Sonneveld P, Ludwig H. *Leukemia.* **2023** Jul 2](#)

[Experts' consensus on the definition and management of high risk multiple myeloma.](#)

Marcon C, Simeon V, Deias P, Facchin G, Corso A, Derudas D, Montefusco V, Offidani M, Petrucci MT, Zambello R, Stocchi R, Fanin R, Patriarca F. *Front Oncol.* **2023** Jan 23;12:1096852.

[Modern imaging techniques for monitoring patients with multiple myeloma.](#) Pop VS, Tomoaia G, Parvu A. *Med Pharm Rep.* **2022**;95:377-384

[Polymorphisms within Autophagy-Related Genes as Susceptibility Biomarkers for Multiple Myeloma: A Meta-Analysis of Three Large Cohorts and Functional Characterization.](#)

Clavero E, Sanchez-Maldonado JM, Macaudo A, Ter Horst R, Sampaio-Marques B, Jurczynszyn A, Clay-Gilmour A, Stein A, Hildebrandt MAT, Weinhold N, Buda G, Garcia-Sanz R, Tomczak W, Vogel U, Jerez A, Zawirska D, Watek M, Hofmann JN, Landi S, Spinelli JJ, Butrym A, Kumar A, Martinez-Lopez J, Galimberti S, Sarasquete ME, Subocz E, Iskierka-Jazdzewska E, Giles GG, Rybicka-Ramos M, Kruszewski M, Abildgaard N, Verdejo FG, Sanchez Rovira P, da Silva Filho MI, Kadar K, Razny M, Cozen W, Pelosini M, Jurado M, Bhatti P, Dudzinski M, Druzd-Sitek A, Orciuolo E, Li Y, Norman AD, Zaucha JM, Reis RM, Markiewicz M, Rodriguez Sevilla JJ, Andersen V, Jamroziak K, Hemminki K, Berndt SI, Rajkumar V, Mazur G, Kumar SK, Ludovico P, Nagler A, Chanock SJ, Dumontet C, Machiela MJ, Varkonyi J, Camp NJ, Ziv E, Vangsted AJ, Brown EE, Campa D, Vachon CM, Netea MG, Canzian F, Försti A, Sainz J. *Int J Mol Sci.* **2023** May 9;24(10):8500

[Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma.](#)

Tantawy M, Yang G, Algubelli RR, DeAvila G, Rubinstein SM, Cornell RF, Fradley MG, Siegel EM, Hampton OA, Silva AS, Lenihan D, Shain KH, Baz RC, Gong Y. *Front Cardiovasc Med.* **2023**;10:1181806

[High Hospital-related Costs at the End-of-life in Patients With Multiple Myeloma: A Single-center Study.](#)

Bennink C, Westgeest H, Schoonen D, Boersen F, Sonneveld P, Hazelzet J, Blommestein H, van der Klift M. *Hemasphere.* **2023**;7:e913

[Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.](#)

Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJA, Blay JY, Italiano A, Yonemori K, Cho DC, de Vos FYFL, Moreau P, Fernandez EE, Schellens JHM, Zielinski CC, Redhu S, Boran A, Passos VQ, Ilankumaran P, Bang YJ. *Nat Med.* **2023** May;29(5):1103-1112

[Health-related quality of life in patients given ciltacabtagene autoleucl for relapsed or refractory multiple myeloma \(CARTITUDE-1\): a phase 1b-2, open-label study.](#)

Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK, Hari P, Berdeja JG, Usmani SZ, Yeh TM, Olyslager Y, Goldberg JD, Schechter JM, Madduri D, Jackson CC, Deraedt W, Gries KS, Fastenau JM, Trudeau JJ, Akram M, Pacaud L, Jakubowiak A, Jagannath S. *Lancet Haematol.* **2022** Dec;9(12):e897-e905

[Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study.](#)

Bennink C, de Mul M, van der Klift M, Broijl A, Tick L, de Jongh E, Garvelink M, Lobbezoo D, Sonneveld P, Hazelzet J. *Patient.* **2023** May;16(3):255-264

[Herbicide use in farming and other jobs in relation to non-Hodgkin's lymphoma \(NHL\) risk.](#)

De Roos AJ, Fritschi L, Ward MH, Monnereau A, Hofmann J, Bernstein L, Bhatti P, Benavente Moreno Y, Benke G, Casabonne D, Clavel J, Cocco P, Huynh T, 't Mannetje A, Miligi L, Piro S, Rothman N, Schinasi LH, Vajdic CM, Wang SS, Zhang Y, Slager SL, Cerhan JR. *Occp Environ Med.* **2022**;79:795-806

Performed 2023, supported + discussed

Black: done
 Green: ✓ = supported by guideline team
 Red: to be discussed
 ↔ Collaborations encouraged

#	Topic	Lead Author/s	Other = Pubmed	EMN GL-team decision
1	Covid recommendations: update 2023	Terpos E.	Leukemia. 2023 Jun;37(6):1175-1185. doi: 10.1038/s41375-023-01920-1	
2	Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the EMN	Ludwig H.	Lancet Oncol. 2023. Jun;24(6):e255-e269. doi: 10.1016/S1470-2045(23)00159-6	
1	Recommendation and management of HR and ultra-HR MM	Kaiser (GB)	Pubmed last 1y, reviews:3 an de Donk NWCJ. JCO 2023 Suzuki K, Yano S. Cancers 2023 Morè S. Cancers 2023 Caro J, Al Hadidi S, Usmani S, Yee AJ, Raje N, Davies FE. Am Soc Clin Oncol Educ Book. 2021 Mar;41:291-309	✓
2	Management of PCL	Musto (IT) + Derudas & Gentile	Pubmed last 5y: 25 van de Donk: Blood. 2012 Sep 20;120(12):2376-89	✓
3	Sequencing of CAR-Ts and TCE	Einsele, van de Donk (G,NL)	Pubmed last 1y: 22 Holstein SA. JCO 2023 Harousseau JL, Mohty M. Blood 2023	✓
4	Management of refractory / progressive disease	Spencer (AUST)	Pubmed last 1y: 146	✓, see: Moreau w IMWG Lancet Oncol 2021
5	a. Recognition, diagnosis and management of monoclonal gammopathy of clinical significance (MGCS) + b. AL-amyloidosis	Kastritis (GR)	Pubmed 1y: 216 publications , i.e. Burgos L. JCO 2023 Oganesyanyan A. Front Immunol. 2022 Gkalea V. Cancers 2023 Chen LY. Haematologica 2023 Dimopoulos for IMWG. Lancet Oncol. 2023	✓ AL-amyloidosis not by EMN ✓ MGCS: covered quite extensive!
6	Coagulation complications of myeloma and their management	Terpos (GR)	Pubmed: plenty, but not covered by IMWG nor EMN, in analogy to AL-Amyloidosis and MGCS	✓ Full support guideline team
7	Preventions & management of side effects with Belantamab	Ludwig, Terpos (A,GR)	In Pubmed last 1y: 43; reviews: 12 Martino EA. Expert Opin Biol Ther. 2023 McCurdy A. Curr Hematol Malig Rep. 2022 Ferreri CJ. Cancer J. 2022 Leong S. Am J Hematol. 2023	Better: ...of Belantamab, Selinexor and Melflufen as non-CAR-Ts or TCE Or of Belmaf, TCE + CAR-Ts (✓) -> wait for DREAMM 8 results 12/23
7	1. Preventive and supportive care in IOs 2. Bone imaging and treatment	Nagarajan (Singapore)	Pubmed last 1y: >100 Ludwig->Lancet Bone: IMWG: Dimopoulos, Terpos	1. Ludwig 2023, 2. various others, collab. with Spencer
8	SMM	Cerchione (IT)	Pubmed last 1y: 9 Last 5 y: 87, i.e. Musto. Hematologica 2021	Last EMN-work: 2021, coll. With Musto
9	1. Use of light chain assays + 2. AL-amyloidosis	Minnema (NL)	Pubmed last 5y: 47 / 361	Collab. with Kastritis
10	1. MRD, 2. Steroid-reduction, 3.EM-MM, 4.Anxiety/stress	Deeren (BE)	Pubmed last 5y: 22 / 0 / 17 / 1	Collab. with Kaiser
11	1. AE management w special interest: infections, 2. BiAb	Liberatore (IT)	Pubmed last 1y: 57 / 54	1. done, 2. w 4+5., coll.w Einsele, van de Donk

Discussion

- **2-4 EMN reviews / guidelines per year, as target is by EMN Board**
 - > Continues to work well, better with meetings in attendance: 2-4 reviews / guidelines 2021, 22, 23
 - > Excellent quality -> leads to acceptance in good + high IF-journals
 - > Good proposals + timely realization for 2023/2024: remains important for EMN's worldwide visibility
- **Prioritize and submit new proposals via EMN guideline team (see EMN homepage and EMN publication policy)**
 - > Has proven to work efficiently + productively
- **EMN manuscript suggestions for 2023: ideas: 11 -> sufficient with 4, if these are realized**
 - > Not all suggested EMN ideas lead to eventually within 1 year achieved EMN-papers, but most (80%), thus is - as planned for 2023 - adequate
- **EMN meeting interaction always helps to increase EMN publication proposals**
 - > Should continue in the same interactive manner to produce highly meaningful, well-cited EMN papers
- EMN board can always be addressed and member ideas are always welcome

General recommendation to authors

Authors interested in making a proposal to EMN are kindly invited to please double check which [topics were already addressed](#) by the network, as well as [this guideline presentation](#) from the EMN **Guideline Group.**